摘要
OBJECTIVE To study the relationship between the serumlevels of IL-18 and IL-18BP in the development and growth ofprimary liver cancer,benign liver tumors and liver cirrhosis and todetermine the value of serum IL-18 and IL-18BP in the diagnosisof primary liver cancer.METHODS The serum levels of IL-18 and IL-18BP in 36 patientswith primary hepatic carcinoma(PHC)were detected.Eighteenpatients were diagnosed with various benign liver tumors and 21patients with cirrhosis of liver(LC),determined by using an ELISAassay.The serum levels of AFP in 36 patients with primary livercancer were examined.The relationship among levels of serumIL-18,IL-18BP and AFP in the primary liver cancer was explored.RESULTS The sIL-18 levels in PHC were significantly lower thanin control group,the benign liver tumor group and the LC group.The sIL-18BP in PHC was significantly higher than that in controlgroup,benign liver tumor group and LC group(P<0.001).Therewas a close correlation between the levels of IL-18,IL-18BP andclinical stage in PHC:the later clinical stages had lower levels ofIL-18 and higher levels of IL-18BP while the earlier clinical stageshad higher levels of IL-18 and lower levels of IL-18BP.There was anegative correlation between serum levels of IL-18 and AFP in thePHC group(r = -0.7152,n=36,P<0.01),and there was a positivecorrelation between serum levels of IL-18 BP and AFP in thepatients with PHC(r=0.6315,n=36,P<0.01).The IL-18 and IL-18BP in the patients with various benign liver tumors or LC weresignificantly higher than those in control group.The differenceswere statistically significant(P<0.01).CONCLUSION Serum levels of IL-18 and IL-18BP can reflectthe immune function of patients with primary liver cancer,withvarious benign liver tumors or with LC and can also be indicativeof the clinic stage of primary liver cancer.It can be used to assistin making a diagnosis and in determining the clinical stage ofPHC.Detecting AFP concurrently can help make the diagnosis ofprimary liver cancer more precise.
OBJECTIVE To study the relationship between the serum levels of IL-18 and IL-18BP in the development and growth of primary liver cancer, benign liver tumors and liver cirrhosis and to determine the value of serum IL-18 and IL-18BP in the diagnosis of primary liver cancer. METHODS The serum levels of IL-18 and IL-18BP in 36 patients with primary hepatic carcinoma （PHC） were detected. Eighteen patients were diagnosed with various benign liver tumors and 21 patients with cirrhosis of liver （LC）, determined by using an ELISA assay. The serum levels of AFP in 36 patients with primary liver cancer were examined. The relationship among levels of serum IL-18, IL-18BP and AFP in the primary liver cancer was explored. RESULTS The sIL-18 levels in PHC were significantly lower than in control group, the benign liver tumor group and the LC group. The sIL-18BP in PHC was significantly higher than that in control group, benign liver tumor group and LC group （P 〈 0.001）. There was a close correlation between the levels of IL-18, IL-18BP and clinical stage in PHC： the later clinical stages had lower levels of IL-18 and higher levels of IL-18BP while the earlier clinical stages had higher levels of IL-18 and lower levels of IL-18BP. There was a negative correlation between serum levels of IL-18 and AFP in the PHC group （r = -0.7152, n = 36, P 〈 0.01）, and there was a positive correlation between serum levels of IL-18 BP and AFP in the patients with PHC （r = 0.6315, n = 36, P 〈 0.01）. The IL-18 and IL- 18BP in the patients with various benign liver tumors or LC were significantly higher than those in control group. The differences were statistically significant （P 〈 0.01）. CONCLUSION Serum levels of IL-18 and IL-18BP can reflect the immune function of patients with primary liver cancer, with various benign liver tumors or with LC and can also be indicative of the clinic stage of primary liver cancer. It can be used to assist in making a diagnosis and in determining the clinical stage of PHC. Detect
基金
supported by a grant from the Zhanjiang Municipal Scientific Research Program,China(No.Zhanke[2005]82-25).
